|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-2-15
|
|
pubmed:abstractText |
Few reports have examined the use of recombinant human thyroid-stimulating hormone (rhTSH) for ablation of postsurgical thyroid remnants after low-dose radioactive iodine (RI) therapy, compared with conventional thyroid hormone withdrawal. We investigated whether patient preparation using rhTSH was comparable to conventional thyroid hormone withdrawal with respect to efficacy of postsurgical remnant ablation in low-risk patients receiving a 30 mCi RI. In addition, we also evaluated the impact of rhTSH (rhTSH vs. conventional thyroid hormone withdrawal) on quality of life (QoL) of thyroid cancer patients undergoing RI ablation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1557-9077
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
173-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20151824-Adult,
pubmed-meshheading:20151824-Carcinoma, Papillary,
pubmed-meshheading:20151824-Combined Modality Therapy,
pubmed-meshheading:20151824-Female,
pubmed-meshheading:20151824-Humans,
pubmed-meshheading:20151824-Hypothyroidism,
pubmed-meshheading:20151824-Iodine Radioisotopes,
pubmed-meshheading:20151824-Male,
pubmed-meshheading:20151824-Middle Aged,
pubmed-meshheading:20151824-Quality of Life,
pubmed-meshheading:20151824-Recombinant Proteins,
pubmed-meshheading:20151824-Substance Withdrawal Syndrome,
pubmed-meshheading:20151824-Thyroid Neoplasms,
pubmed-meshheading:20151824-Thyrotropin,
pubmed-meshheading:20151824-Thyroxine,
pubmed-meshheading:20151824-Treatment Outcome,
pubmed-meshheading:20151824-Triiodothyronine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
|
|
pubmed:affiliation |
Department of Surgery, Ajou University School of Medicine, Suwon, Republic of Korea.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
